7

Ex. 4). In 2016, Mylan filed an Abbreviated New Drug Application (ANDA) with the FDA, seeking approval of a generic colchicine product. (DI. 92, Meckstroth Decl., 116). Based on

  • Upload
    others

  • View
    1

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Ex. 4). In 2016, Mylan filed an Abbreviated New Drug Application (ANDA) with the FDA, seeking approval of a generic colchicine product. (DI. 92, Meckstroth Decl., 116). Based on
Page 2: Ex. 4). In 2016, Mylan filed an Abbreviated New Drug Application (ANDA) with the FDA, seeking approval of a generic colchicine product. (DI. 92, Meckstroth Decl., 116). Based on
Page 3: Ex. 4). In 2016, Mylan filed an Abbreviated New Drug Application (ANDA) with the FDA, seeking approval of a generic colchicine product. (DI. 92, Meckstroth Decl., 116). Based on
Page 4: Ex. 4). In 2016, Mylan filed an Abbreviated New Drug Application (ANDA) with the FDA, seeking approval of a generic colchicine product. (DI. 92, Meckstroth Decl., 116). Based on
Page 5: Ex. 4). In 2016, Mylan filed an Abbreviated New Drug Application (ANDA) with the FDA, seeking approval of a generic colchicine product. (DI. 92, Meckstroth Decl., 116). Based on
Page 6: Ex. 4). In 2016, Mylan filed an Abbreviated New Drug Application (ANDA) with the FDA, seeking approval of a generic colchicine product. (DI. 92, Meckstroth Decl., 116). Based on
Page 7: Ex. 4). In 2016, Mylan filed an Abbreviated New Drug Application (ANDA) with the FDA, seeking approval of a generic colchicine product. (DI. 92, Meckstroth Decl., 116). Based on